Evidence map›Paper›PMID 40461968›Full record

ArticleBMC cancer2025

CEBPB promotes transformation of endometrial complex atypical hyperplasia to endometrial cancer.

Jiahong Tan, Lin Zhao, Daoqi Wang, Xiaodie Wu, Yongxiang Bi, Hanying Wang, Na Ma, Dehong Yang, Wei Dong, Jie Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jiahong TanDepartment of Obstetrics and Gynecology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No.157 Jinbi Road, Kunming, 650032, People's Republic of China.
Lin ZhaoDepartment of Obstetrics and Gynecology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No.157 Jinbi Road, Kunming, 650032, People's Republic of China.
Daoqi WangDepartment of Urology, The Second Affiliated Hospital of Kunming Medical University, No.374 Dianmian Avenue, Kunming, 650101, People's Republic of China. daoqi_w@163.com.
Xiaodie WuDepartment of Obstetrics and Gynecology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No.157 Jinbi Road, Kunming, 650032, People's Republic of China.
Yongxiang BiDepartment of Obstetrics and Gynecology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No.157 Jinbi Road, Kunming, 650032, People's Republic of China.
Hanying WangDepartment of Obstetrics and Gynecology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No.157 Jinbi Road, Kunming, 650032, People's Republic of China.
Na MaDepartment of Obstetrics and Gynecology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No.157 Jinbi Road, Kunming, 650032, People's Republic of China.
Dehong YangDepartment of Obstetrics and Gynecology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No.157 Jinbi Road, Kunming, 650032, People's Republic of China.
Wei DongDepartment of Obstetrics and Gynecology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No.157 Jinbi Road, Kunming, 650032, People's Republic of China. Weiwei_d@126.com.
Jie ZhangDepartment of Obstetrics and Gynecology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No.157 Jinbi Road, Kunming, 650032, People's Republic of China.

Funding

Basic Research Project of Yunnan Province 202301AT070041, 202301AT070259Doctoral Research Fund Program of the First Pelple's Hospital of Yunnan Province KHBS-2022-026First People's Hospital of Yunnan Province・National Key Clinical Specialty of Gynecology 2022FKZDZK-16High-level Personnel Introduction Fund of the First People's Hospital of Yunnan Province 2022-KHRCBZ-B05Joint Special Funds for the Department of Science and Technology of Yunnan Province‑Kunming Medical University 202401AY070001-012National Natural Science Foundation of China 82203145Yunnan Provincial Clinical Medical Center for Reproductive, Gynecological and Obstetrical Diseases 2022LCZXKF-SZ08Yunnan Revitalization Talent Support Program XDYC-QNRC-2023-0440
6 · The paper itself

Abstract

backgroundAs the precursor malignancy of endometrial cancer (EC), about 50% of endometrial complex atypical hyperplasia (CAH) will eventually progress to EC. Elucidating the underlying transformation mechanisms could aid in disease management.

methodsEC, CAH, reversed CAH and normal endometrium tissues were collected and sequenced to identify genes involved in the malignant transformation. CEBPB expression was then compared between endometrial CAH and normal endometrium. After evaluation of its effects on proliferation, apoptosis, EMT, migration and invasion by using primary culture, the promotion effects of CEBPB on endometrial CAH were further confirmed using RNA sequencing.

resultsBy integrating RNA sequencing data, CEBPB was identified as implicated in the transformation from endometrial CAH to EC. Endometrial CAH had overexpressed CEBPB compared with normal endometrium, but the expression decreased as the disease reversed. Primary cultures of CAH had enhanced proliferation, EMT, migration and invasion but reduced apoptosis compared with that of normal endometrium. Knockdown CEBPB in CAH primary cultures could suppress the proliferation, EMT, migration and invasion while increasing apoptosis, rendering the disease phenotype. Genes regulated by CEBPB were also significantly enriched in pathways related to the malignant transformation.

conclusionsCEBPB is involved in endometrial CAH and promotes the transformation from CAH to EC. CEBPB could potentially be exploited as a surrogate screening and surveillance biomarker for endometrial CAH at high cancerous risk, enabling better risk stratification and individualized treatment.

Indexed as

CCAAT-Enhancer-Binding Protein-betaCell Transformation, NeoplasticEndometrial HyperplasiaEndometrial NeoplasmsApoptosisCell MovementCell ProliferationEndometriumEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHumansMiddle AgedCCAAT-Enhancer-Binding Protein-betaCEBPB protein, humanBiomarkerCEBPBEndometrial cancerEndometrial complex atypical hyperplasiaTransformation

Identifiers

PMID40461968
PMCPMC12131642

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.